RHB analyst Jarick Seet has downgraded his call on medical oncology and stem cell services provider TalkMed to “hold” from his previous “buy” call.
His move comes as international medical tourists – which forms the bulk of TalkMed’s patients – takes a hit from the ongoing travel restrictions imposed to curb the spread of Covid-19 infections.
This caused a 23.2% plunge in its revenue to $14.1 million.
